Antibody therapy market to reach nearly $700 billion by 2032

With an estimated compound annual growth rate (CAGR) of 12.8% during the projected period, the  antibody therapy market share is expected to reach $700 billion by 2032, up from $186 billion in a report published by FMI. The study finds that the rising demand for Humira (adalimumab) proportionately reflects on the adoption of antibody therapy.

COVID-19 has caused the world to come to a halt. We know that this health crisis had a significant impact on businesses in all different types of businesses. The pandemic is expected to have an effect on almost every part of the economy. The healthcare industry had a big problem at the start of the supply chain.

Trade growth for monoclonal antibody (Mab) treatment has slowed down for the big players in the market. If you look at the information on monoclonal antibody therapy in the market, it's broken down into human monoclonal antibody, humanized antibody, a chimeric antibody, and murine monoclonal antibody treatment.